Here are the 10-K annual reports from Estrella Immunopharma, Inc. (ESLA) in our archive since June 2025, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-K covers the audited annual report, with the full financial statements, so if you follow ESLA and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full ESLA filings page.
Estrella Immunopharma, Inc. filed an amended annual report to add detailed disclosures on board composition, executive compensation, ownership and auditor matters for the period ended December 31, 2025. The filing confirms a seven‑member board, three key committees, and independence status for several directors.
The amendment shows the CEO and CFO each earned salary of $250,962 in 2025, with prior equity awards under the 2023 Omnibus Incentive Plan. As of March 12, 2026, 42,665,228 common shares were outstanding and Eureka Therapeutics, Inc. beneficially owned about 59.3% of the stock, making Estrella a controlled company under Nasdaq rules.
Estrella Immunopharma, Inc. files its annual report describing progress as a clinical-stage biopharmaceutical company developing ARTEMIS T‑cell therapies for cancers and autoimmune diseases. Its lead CD19‑directed candidate, EB103, completed the Phase I dose‑escalation portion of the STARLIGHT‑1 trial in relapsed/refractory B‑cell non‑Hodgkin lymphomas.
In Phase I (n=9), no treatment‑related serious adverse events were reported and all cytokine release syndrome events were Grade 1–2. The high‑dose cohort achieved a 100% complete response rate at Month 1 in all 5 evaluable patients, with responses remaining in remission as of January 28, 2026. An independent safety board recommended advancing to Phase II, and dosing has begun.
Estrella is also advancing dual‑target CD19/CD22 candidate EB104, preclinical autoimmune program EB201 for lupus, and a “mark and kill” solid‑tumor collaboration using CF33‑CD19t with Imugene. As of March 12, 2026, market value of non‑affiliate equity was $20,496,203 with 42,665,228 common shares outstanding.